|
![]() |
|
|
Captopril: profile and news
Attempts to Recruit Stem Cells for Repair of Acute Myocardial ... Feb 28, 2006 Coughing fits stump doctors Feb 8, 2006 Coughing fits stump doctors Feb 8, 2006 New drugs use saliva to help relieve pain Jan 10, 2006 Loss of taste, smell often tied to high blood pressure, meds Jan 24, 2006 Side benefits of ACE inhibitors Dec 4, 2005 Aging just one cause for loss of taste Nov 21, 2005 Anti-anxiety treatment found effective in lowering blood pressure Oct 9, 2005 Good news for heart attack survivors Sep 21, 2005 What to do when you're lacking in taste Sep 19, 2005 FDA Approvals: Diovan, Celebrex, Adderall XR Aug 4, 2005 Diovan to reduce cardiovascular death in heart attack survivors at ... Aug 5, 2005 UPDATE 1-FDA OKs new uses for Novartis blood pressure drug Aug 3, 2005 FDA Approves Diovan(R) (Valsartan) to Reduce Cardiovascular Death ... Aug 3, 2005 Race influences prostate cancer behavior Jul 29, 2005 McKesson plans outsourcing deals in India Jun 28, 2005 Keryx Biopharmaceuticals, Inc. Initiates Pivotal Phase 3 and Phase ... Jun 29, 2005 Treatment offers hope for heart attack survivors in the Middle ... Jun 13, 2005 Risk of Sudden Death and Cardiac Arrest is Greatest in 30 Days ... Jun 22, 2005 Diovan receives EU approval to treat people after heart attacks May 27, 2005 Risk of Sudden Death and Cardiac Arrest is Greatest in 30 Days ... Jun 22, 2005 Treatment offers hope for heart attack survivors in the Middle ... Jun 13, 2005 Hemispherx Biopharma's Investigational Drug Increases Physical ... Apr 11, 2005 Venom as a Prelude to New Drug Treatments Mar 6, 2005 Many things can cause metallic taste Feb 28, 2005 Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor ... Feb 28, 2005 Diagnosis and Treatment of Renovascular Hypertension: A Cost ... Feb 23, 2005 BCBSNC Launches New Prescription Drug Savings Initiative Feb 17, 2005 Update on Risk Factors for Atherosclerosis: The Role of ... Feb 26, 2005 Other information Indication For the treatment of hypertension. It may be used alone or in combination with thiazide diuretics Pharmacology Captopril, an angiotensin-converting enzyme (ACE) inhibitor, is used to treat hypertension, congestive heart failure, and renal syndromes such as diabetic nephropathy and scleroderma. Mechanism Of Action Captopril competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. As angiotensin II is a vasoconstrictor and a negative feedback mediator for renin activity, lower angiotensin II levels results in a decrease in blood pressure, an increase in renin activity, and stimulation of baroreceptor reflex mechanisms. Kininase II, an enzyme which degrades the vasodilator bradykinin, is identical to ACE and may also be inhibited. Drug Category Antihypertensive Agents; Angiotensin-converting Enzyme Inhibitors; ATC:C09AA01 Brand Names/Synonyms Acediur; Aceplus; Acepress; Acepril; Alopresin; Apopril; Capoten; Capozide; Captolane; Captopril; Captopril [Usan:Ban:Inn:Jan]; Captoprilum [Inn-Latin]; Captopryl; Captoril; Cesplon; Dilabar; Garranil; HSDB 6527; Hipertil; Hypertil; L-Captopril; Lopirin; Lopirin [Switzerland]; Lopril; SA 333; Tenosbon; Tensobon; Tensoprel Dosage Forms in potencies of 12.5, 25, 50, 100mg as scored tablets Absorption 75% without food Interactions -->Interactions for Captopril: Hypotension ó Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of captopril. The possibility of hypotensive effects with captopril can be minimized by either discontinuing the diuretic or increasing the salt intake approximately one week prior to initiation of treatment with captopril (captopril tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg). Alternatively, provide medical supervision for at least one hour after the initial dose. If hypotension occurs, the patient should be placed in a supine position and, if necessary, receive an intravenous infusion of normal saline. This transient hypotensive response is not a contraindication to further doses which can be given without difficulty once the blood pressure has increased after volume expansion. Agents Having Vasodilator Activity: Data on the effect of concomitant use of other vasodilators in patients receiving captopril for heart failure are not available; therefore, nitroglycerin or other nitrates (as used for management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting captopril. If resumed during captopril therapy, such agents should be administered cautiously, and perhaps at lower dosage. Agents Causing Renin Release Captoprilís effect will be augmented by antihypertensive agents that cause renin release. For example, diuretics (e.g., thiazides) may activate the renin-angiotensin-aldosterone system. Agents Affecting Sympathetic Activity The sympathetic nervous system may be especially important in supporting blood pressure in patients receiving captopril alone or with diuretics. Therefore, agents affecting sympathetic activity (e.g., ganglionic blocking agents or adrenergic neuron blocking agents) should be used with caution. Beta-adrenergic blocking drugs add some further antihypertensive effect to captopril, but the overall response is less than additive. Agents Increasing Serum Potassium Since captopril decreases aldosterone production, elevation of serum potassium may occur. Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium. Salt substitutes containing potassium should also be used with caution. Inhibitors Of Endogenous Prostaglandin Synthesis It has been reported that indomethacin may reduce the antihypertensive effect of captopril, especially in cases of low renin hypertension. Other nonsteroidal anti-inflammatory agents (e.g., aspirin) may also have this effect. Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. These drugs should be coad-ministered with caution and frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, it may increase the risk of lithium toxicity. Cardiac Glycosides In a study of young healthy male subjects no evidence of a direct pharmacokinetic captopril-digoxin interaction could be found. Loop Diuretics: Furosemide administered concurrently with cap-topril does not alter the pharmacokinetics of captopril in renally impaired hypertensive patients. Allopurinol In a study of healthy male volunteers no significant pharmacokinetic interaction occurred when captopril and allop-urinol were administered concomitantly for 6 days. Drug/Laboratory Test Interaction Captopril may cause a false-positive urine test for acetone. Chemical IUPAC Name 1-(2-methyl-3-sulfanyl-propanoyl)pyrrolidine-2-carboxylicacid Chemical Formula C9H15NO3S Half Life < 3 hours Drug Type Approved Drug # Accession No APRD00164 CAS Registry Number 62571-86-2 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |